Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
| Autor: | Hisashi Kaneko, Satoshi Takai, Masayuki Kurokawa, Suguru Ito, Sei Naito, Yuko Kawamura, Hiroshi Kakizaki, Norihiko Tsuchiya |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Metastatic Urothelial Carcinoma Urology Case Report autoimmune disease Pembrolizumab overlap syndrome lcsh:RC870-923 Internal medicine medicine Adverse effect Lymph node Autoimmune disease renal pelvic cancer business.industry Cancer Overlap syndrome lcsh:Diseases of the genitourinary system. Urology medicine.disease medicine.anatomical_structure metastatic urothelial carcinoma Prednisolone pembrolizumab business medicine.drug |
| Zdroj: | IJU Case Reports, Vol 3, Iss 5, Pp 181-183 (2020) IJU Case Reports |
| ISSN: | 2577-171X |
| Popis: | Introduction The safety and efficacy of pembrolizumab administration in patients with urothelial carcinoma and underlying autoimmune disease (including overlap syndrome) is unknown. Case presentation We present the case of a 67-year-old woman with cT3N2M0 metastatic renal pelvic cancer who had been treated with prednisolone for overlap syndrome involving systemic sclerosis and systemic lupus erythematosus for 20 years. She had a remarkable response to pembrolizumab as a third-line systemic therapy, wherein the tumor reduced in size and all regional lymph node and pulmonary metastases disappeared. She did not develop any immune-related adverse events or autoimmune disease flare-ups during the treatment. Conclusion This case report suggests that pembrolizumab could be beneficial to patients with urothelial carcinoma and underlying well-controlled overlap syndrome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text